## Jan Styczynski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3907779/publications.pdf

Version: 2024-02-01

249 papers 7,048 citations

38 h-index 71651 **76** g-index

269 all docs

269 docs citations

times ranked

269

8064 citing authors

#	Article	IF	CITATIONS
1	<i>Nocardia</i> Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2022, 75, 88-97.	2.9	15
2	HEV infection in stem cell transplant recipientsâ€"retrospective study of EBMT Infectious Diseases Working Party. Bone Marrow Transplantation, 2022, 57, 167-175.	1.3	6
3	Discrepancies in the management of Clostridioides difficile infections in patients after allogeneic haematopoietic cell transplantation: the results of the Infectious Diseases Working Party EBMT survey. Bone Marrow Transplantation, 2022, , .	1.3	1
4	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia, 2022, 36, 1467-1480.	3 <b>.</b> 3	63
5	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine, 2022, 11, 3541.	1.0	4
6	Infections With Stenotrophomonas maltophilia in Children Undergoing Anticancer Therapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. Pediatric Infectious Disease Journal, 2022, 41, 846-850.	1.1	4
7	Prevalence, Epidemiology, Etiology, and Sensitivity of Invasive Bacterial Infections in Pediatric Patients Undergoing Oncological Treatment: A Multicenter Nationwide Study. Microbial Drug Resistance, 2021, 27, 53-63.	0.9	6
8	Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome. Clinical Cancer Research, 2021, 27, 575-584.	3.2	13
9	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplantation, 2021, 56, 1171-1179.	1.3	30
10	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2021, 223, 1564-1575.	1.9	21
11	Clinical Spectrum and Outcomes of Neonatal Necrotizing Enterocolitis. In Vivo, 2021, 35, 585-591.	0.6	4
12	Killer-cell immunoglobulin-like receptor genotype and haplotype combinations in children treated for acute lymphoblastic leukemia. Central-European Journal of Immunology, 2021, 46, 210-216.	0.4	1
13	Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Annals of Hematology, 2021, 100, 763-777.	0.8	8
14	Contribution of nurses to protective environment in haematopoietic cell transplant setting: an international survey by the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2021, 56, 1433-1440.	1.3	3
15	Management of Herpesvirus Infections in Hematopoietic Cell Transplant Recipients. Transplantology, 2021, 2, 8-21.	0.3	6
16	Legionellosis after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2555-2566.	1.3	1
17	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia, 2021, 35, 2885-2894.	3.3	153
18	8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncology, The, 2021, 22, e254-e269.	5.1	89

#	Article	IF	CITATIONS
19	8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncology, The, 2021, 22, e270-e280.	5.1	65
20	Impact of decontamination therapy on gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in children. Current Research in Translational Medicine, 2021, 69, 103298.	1.2	3
21	Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertionâ€"multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT. Bone Marrow Transplantation, 2021. 56. 2929-2933.	1.3	2
22	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP–EBMT. Bone Marrow Transplantation, 2021, 56, 1563-1572.	1.3	1
23	Management of PTLD After HSCT., 2021, , 221-237.		0
24	Acute Lymphoblastic Leukemia in Children: Better Transplant Outcomes After Total Body Irradiation-based Conditioning. In Vivo, 2021, 35, 3315-3320.	0.6	6
25	Program Racjonalnej Terapii Przeciwgrzybiczej "WYLECZ!― Forum ZakażeÅ,,, 2021, 12, 133-138.	0.0	0
26	Analysis of incidence and risk factors of the multidrug resistant gastrointestinal tract infection in children and adolescents undergoing allogeneic and autologous hematopoietic cell transplantation: a nationwide study. Annals of Hematology, 2021, 101, 191.	0.8	1
27	COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study. Journal of Hematology and Oncology, 2021, 14, 163.	6.9	19
28	Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – study of Infectious Diseases Working Party of EBMT. Journal of Infection, 2021, , .	1.7	2
29	The urinary excretion of epigenetically modified DNA as a marker of pediatric ALL status and chemotherapy response. Scientific Reports, 2021, 11, 21345.	1.6	3
30	COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). Blood, 2021, 138, 2866-2866.	0.6	4
31	Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARSâ€CoVâ€2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT. Transplant Infectious Disease, 2021, , .	0.7	2
32	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	1.3	61
33	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplantation, 2020, 55, 126-136.	1.3	196
34	Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT. Bone Marrow Transplantation, 2020, 55, 110-116.	1.3	15
35	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIE). Bone Marrow Transplantation, 2020, 55, 681-694.	1.3	39
36	Multidrugâ€resistant bacterial infections in children undergoing haematopoietic stem cell transplantation over a 6â€year period: analysis of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. Journal of Applied Microbiology, 2020, 128, 292-300.	1.4	2

#	Article	IF	CITATIONS
37	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316.	1.7	230
38	Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality. Journal of Infection, 2020, 81, 882-894.	1.7	9
39	Minimally Invasive Surgery for Congenital Abdominal Cystic Lesions in Newborns and Infants. In Vivo, 2020, 34, 1215-1221.	0.6	5
40	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation, 2020, 55, 2071-2076.	1.3	163
41	BK virus infection in allogeneic hematopoietic cell transplantation: An update on pathogenesis, immune responses, diagnosis and treatments. Journal of Infection, 2020, 81, 372-382.	1.7	14
42	Infectious complications after hematopoietic stem cell transplantation for primary immunodeficiency in children: A multicenter nationwide study. Pediatric Allergy and Immunology, 2020, 31, 537-543.	1.1	6
43	Adenovirus infection among pediatric patients with cancer and in pediatric recipients of hematopoietic stem cell: A multicenter nationwide study. Journal of Medical Virology, 2020, 92, 3187-3193.	2.5	8
44	Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplantation, 2020, 55, 1996-2007.	1.3	18
45	Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman–Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT). Bone Marrow Transplantation. 2020. 55. 1796-1809.	1.3	25
46	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?â€"A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, 55, 1540-1551.	1.3	42
47	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. Bone Marrow Transplantation, 2020, 55, 1604-1613.	1.3	147
48	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWPâ€EBMT, EORTCâ€IDG and SEIFEM survey. Mycoses, 2020, 63, 420-429.	1.8	7
49	Diagnostic Algorithm in Hirschsprung's Disease: Focus on Immunohistochemistry Markers. In Vivo, 2020, 34, 1355-1359.	0.6	7
50	New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications. Anticancer Research, 2020, 40, 1817-1831.	0.5	17
51	Hematopoietic stem cell transplantation does not increase the risk of infectionâ€related complications for pediatric patients with Hodgkin and nonâ€Hodgkin lymphomas: A multicenter nationwide study. Transplant Infectious Disease, 2020, 22, e13292.	0.7	0
52	Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. Transplantation Proceedings, 2020, 52, 2178-2185.	0.3	12
53	Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplantation, 2020, 55, 1588-1594.	1.3	37
54	How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Advances, 2020, 4, 6283-6290.	2.5	89

#	Article	IF	CITATIONS
55	A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica, 2020, 51, 2-5.	0.1	32
56	Prophylaxis vs preemptive therapy in prevention of CMV infection: new insight on prophylactic strategy after allogeneic hematopoietic cell transplantation. Acta Haematologica Polonica, 2020, 51, 17-23.	0.1	10
57	Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Acta Haematologica Polonica. 2020. 51, 73-80.	0.1	6
58	Clinical spectrum and outcome of invasive mucormycosis in children and adults: Polish experience of the decade 2010–2019. Acta Haematologica Polonica, 2020, 51, 157-163.	0.1	1
59	Antimicrobial prophylaxis in patients after hematopoietic cell transplantation: results of a survey of the Polish Federation of Bone Marrow Transplant Centers. Acta Haematologica Polonica, 2020, 51, 183-186.	0.1	1
60	Impact of oral decontamination on acute graft-versus-host disease and overall survival in children undergoing allogeneic hematopoietic cell transplantation. Acta Haematologica Polonica, 2020, 51, 187-190.	0.1	1
61	Eltrombopag use in chronic immune thrombocytopenia of childhood: results from nationwide therapeutic program. Acta Haematologica Polonica, 2020, 51, 226-229.	0.1	0
62	Efficacy of keratinocyte growth factor in prevention of oral mucositis in children undergoing allogeneic hematopoietic cell transplantation. Acta Haematologica Polonica, 2020, 51, 172-178.	0.1	1
63	Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation. Anticancer Research, 2020, 40, 6531-6537.	0.5	1
64	Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: Impact of national programme of antifungal prophylaxis. Mycoses, 2019, 62, 990-998.	1.8	12
65	Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. Annals of Hematology, 2019, 98, 2197-2211.	0.8	25
66	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. Bone Marrow Transplantation, 2019, 54, 2060-2071.	1.3	6
67	Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. Clinical and Experimental Hepatology, 2019, 5, 195-202.	0.6	22
68	Minimally Invasive Surgery in Pediatric Oncology: Proposal of Guidelines. Anticancer Research, 2019, 39, 5853-5859.	0.5	10
69	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematology,the, 2019, 6, e573-e584.	2.2	140
70	Infection profile in children and adolescents with bone marrow failures treated with allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation, 2019, 23, e13592.	0.5	1
71	Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress. Anticancer Research, 2019, 39, 5203-5207.	0.5	16
72	<p>Infectious complications in children with malignant bone tumors: a multicenter nationwide study</p> . Infection and Drug Resistance, 2019, Volume 12, 1471-1480.	1.1	13

#	Article	IF	CITATIONS
73	Infectious profile in children with ALL during chemotherapy: A report of study group for infections. Journal of Infection and Chemotherapy, 2019, 25, 774-779.	0.8	12
74	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Annals of Hematology, 2019, 98, 1755-1763.	0.8	35
75	<i>GATA3</i> germline variant is associated with <i>CRLF2</i> expression and predicts outcome in pediatric Bâ€eell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 619-626.	1.5	9
76	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	1.3	218
77	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation, 2019, 54, 1575-1585.	1.3	129
78	Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein–Barr Virus Reactivation. Infection and Drug Resistance, 2019, Volume 12, 3893-3902.	1.1	11
79	Lymphocyte Subpopulations in Patients With Neurofibromatosis Type 1-associated Optic Pathway Gliomas and Plexiform Neurofibromas. Anticancer Research, 2019, 39, 6389-6392.	0.5	1
80	Complex profile of multiple hepatobiliary and gastrointestinal complications after hematopoietic stem cell transplantation in a child with Nijmegen breakage syndrome. Central-European Journal of Immunology, 2019, 44, 327-331.	0.4	2
81	A survey on incidence and management of adenovirus infection after allogeneic HSCT. Bone Marrow Transplantation, 2019, 54, 1275-1280.	1.3	24
82	Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology. Leukemia and Lymphoma, 2019, 60, 124-132.	0.6	5
83	Low seroprevalence and low incidence of infection with Toxoplasma gondii (Nicolle et Manceaux,) Tj ETQq1 1 0.78 Folia Parasitologica, 2019, 66, .	34314 rgB 0.7	
84	ABC of viral infections in hematology: focus on herpesviruses. Acta Haematologica Polonica, 2019, 50, 159-166.	0.1	6
85	Infectious complications in children and adults with hematological malignancies. Acta Haematologica Polonica, 2019, 50, 167-173.	0.1	6
86	Post transplant Lymphoproliferative Syndromes. , 2019, , 347-352.		2
87	ZagroŹ⁄4enie inwazyjnymi zakaŹ⁄4eniami grzybiczymi u pacjentów po przeszczepieniu komórek krwiotwórczych: wskazówki dotyczÄ…ce Å≀rodowiskowego postÄ™powania profilaktycznego. Forum ZakaŹ⁄46 2019, 10, 99-104.	<b>?Å</b> ),,О	0
88	Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2018, 67, 564-572.	2.9	30
89	Management of adenovirus infection in patients after haematopoietic stem cell transplantation: Stateâ€ofâ€theâ€art and realâ€life current approach. Reviews in Medical Virology, 2018, 28, e1980.	3.9	75
90	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplantation, 2018, 53, 422-430.	1.3	24

#	Article	IF	Citations
91	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1548-1552.	1.3	6
92	HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor. Human Immunology, 2018, 79, 403-412.	1.2	9
93	Protective environment for hematopoietic cell transplant (HSCT) recipients: The Infectious Diseases Working Party EBMT analysis of global recommendations on health-care facilities. Bone Marrow Transplantation, 2018, 53, 1131-1138.	1.3	17
94	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2018, 53, 1139-1148.	1.3	117
95	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection, 2018, 76, 20-37.	1.7	125
96	Role of PET T in management of posttransplant lymphoproliferative disorder. Pediatric Blood and Cancer, 2018, 65, e26741.	0.8	3
97	Heterozygous carriers of germline c.657_661del5 founder mutation in <i>NBN</i> gene are at risk of central nervous system relapse of B-cell precursor acute lymphoblastic leukemia. Haematologica, 2018, 103, e200-e203.	1.7	5
98	Impact of CMV and EBV on Immune Recovery After Allogeneic Hematopoietic Cell Transplantation in Children. Anticancer Research, 2018, 38, 6009-6013.	0.5	6
99	X-linked TLR7 gene polymorphisms are associated with diverse immunological conditions but not with discoid lupus erythematosus in Polish patients. Postepy Dermatologii I Alergologii, 2018, 35, 26-32.	0.4	6
100	Demographical Profile and Spectrum of Multiple Malignancies in Children and Adults with Neurocutaneous Disorders. Anticancer Research, 2018, 38, 5453-5457.	0.5	7
101	Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 2101-2109.	2.0	32
102	Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology. Transfusion and Apheresis Science, 2018, 57, 316-322.	0.5	4
103	Young child as a donor of cells for transplantation and lymphocyte based therapies. Transfusion and Apheresis Science, 2018, 57, 323-330.	0.5	6
104	Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1805-1812.	1.3	22
105	Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation. Infectious Diseases and Therapy, 2018, 7, 1-16.	1.8	114
106	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 2120-2120.	0.6	11
107	Analysis of Risk Factors Determining Incidence and Outcome of Infections in Children and Adults after Hematopoietic Cell Transplantation. Blood, 2018, 132, 3364-3364.	0.6	0
108	Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies. Blood, 2018, 132, 3354-3354.	0.6	0

#	Article	IF	Citations
109	ZakaŽenia wirusowe u dzieci po przeszczepieniu komórek krwiotwórczych: raport 2016 Polskiej Pediatrycznej Grupy ds. Zakażeń, Polskiego Towarzystwa Onkologii i Hematologii Dziecięcej. Acta Haematologica Polonica, 2017, 48, 23-27.	0.1	2
110	Role of HLA match on results of hematopoietic stem cell transplantations from unrelated donors in children with acute leukemia and bone marrow failure syndromes. Acta Haematologica Polonica, 2017, 48, 48-53.	0.1	3
111	Managing post-transplant lymphoproliferative disorder. Expert Opinion on Orphan Drugs, 2017, 5, 19-35.	0.5	9
112	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2017, 52, 811-817.	1.3	310
113	Conscious sedation or general anaesthesia for lumbar puncture in children in Poland. Lancet, The, 2017, 390, 1025.	6.3	1
114	Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clinical Infectious Diseases, 2017, 65, 1819-1828.	2.9	179
115	CAR-T cells: the narrow path between hope and bankruptcy?. Bone Marrow Transplantation, 2017, 52, 1588-1589.	1.3	24
116	Incidence of Infectious Complications in Children With Acute Lymphoblastic Leukemia Treated With Hematopoietic Stem Cell Transplantation. Transplantation Proceedings, 2017, 49, 2183-2187.	0.3	3
117	No report on Zika virus infection in EBMT registry: Infectious Diseases Working Party statement. Bone Marrow Transplantation, 2017, 52, 1345-1346.	1.3	3
118	Biallelic loss of <i>CDKN2A</i> is associated with poor response to treatment in pediatric acute lymphoblastic leukemia. Leukemia and Lymphoma, 2017, 58, 1162-1171.	0.6	43
119	Massively parallel targeted resequencing reveals novel genetic variants associated with aspergillosis in paediatric patients with haematological malignancies. Polish Journal of Pathology, 2017, 68, 210-217.	0.1	7
120	Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification. Anticancer Research, 2017, 37, 6551-6556.	0.5	20
121	Third-party Wharton's jelly mesenchymal stem cells for treatment of steroid-resistant acute and chronic graft-versus-host disease: a report of 10 cases. Turkish Journal of Biology, 2016, 40, 493-500.	2.1	3
122	Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica, 2016, 101, 803-811.	1.7	273
123	Genomic and transcriptomic profiles and <i>in vitro</i> resistance to mitoxantrone and idarubicin in pediatric acute leukemias. Journal of Gene Medicine, 2016, 18, 165-179.	1.4	6
124	Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2016, 34, 2212-2220.	0.8	41
125	Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. Transplant Infectious Disease, 2016, 18, 690-698.	0.7	19
126	Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation. Leukemia and Lymphoma, 2016, 57, 2456-2459.	0.6	1

#	Article	IF	CITATIONS
127	Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biology of Blood and Marrow Transplantation, 2016, 22, 96-103.	2.0	35
128	Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clinical Microbiology and Infection, 2016, 22, 179.e1-179.e10.	2.8	68
129	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 988-988.	0.6	1
130	Recommendations for the diagnosis and treatment of CMV infections. Polish Society of Epidemiology and Infectious Diseases. Przeglad Epidemiologiczny, 2016, 70, 297-310.	0.4	4
131	Current practices used for the prevention of central venous catheterâ€associated infection in hematopoietic stem cell transplantation recipients: a survey from the Infectious Diseases Working Party and Nurses' Group of <scp>EBMT</scp> . Transplant Infectious Disease, 2015, 17, 558-565.	0.7	9
132	Phenotype of NK Cells Determined on the Basis of Selected Immunological Parameters in Children Treated due to Acute Lymphoblastic Leukemia. Medicine (United States), 2015, 94, e2369.	0.4	4
133	Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection?. Bone Marrow Transplantation, 2015, 50, 899-903.	1.3	40
134	Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 385-395.	1.0	2
135	Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options – a Retrospective Analysis. Journal of Clinical Immunology, 2015, 35, 538-549.	2.0	73
136	Results of therapy in children with acute lymphoblastic leukemia in over 50 years of experience in a single center in Poland. Leukemia and Lymphoma, 2015, 56, 2212-2214.	0.6	5
137	Whole Genome and Transcriptome Analysis of Genetic Alterations in Context of Busulfan in Vitro Resistance in Pediatric Acute Leukemias. Blood, 2015, 126, 4849-4849.	0.6	1
138	Identification of the Genomic Rearrangements Associated with the Ex Vivo Resistance to Anthracyclines in Childhood Acute Leukemias. Blood, 2015, 126, 4997-4997.	0.6	1
139	Differential in Vitro Drug Resistance Profile Between First and Second Relapsed Acute Lymphoblastic Leukemia and Acute Myeloblastic Leukemia in Children. Blood, 2015, 126, 3696-3696.	0.6	0
140	Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia. Anticancer Research, 2015, 35, 5667-70.	0.5	13
141	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncology, The, 2014, 15, e327-e340.	5.1	325
142	Viral infection-oxidative stress/DNA damage-aberrant DNA methylation: separate or interrelated events responsible for genetic instability and childhood ALL development?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 226-231.	3.3	8
143	Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2014, 59, 473-481.	2.9	201
144	Wysokie dawki cyklofosfamidu po niemieloablacyjnym haploidentycznym przeszczepieniu komórek krwiotwórczych u dziecka z nawrotowÄ postaciÄ nerwiaka zarodkowego: krok w kierunku rozdzielenia reakcji GVT i GVH. Acta Haematologica Polonica, 2014, 45, 279-283.	0.1	0

#	Article	IF	Citations
145	Treosulfan-Based Conditioning before Hematopoietic Stem Cell Transplantation: Analysis of Differences Between Children and Adults. Biology of Blood and Marrow Transplantation, 2014, 20, S251-S252.	2.0	0
146	Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance. Blood, 2014, 124, 3802-3802.	0.6	1
147	INFECTIONS IN POLISH PEDIATRIC HEMATOLOGY, ONCOLOGY AND STEM CELL TRANSPLANTATION CENTERS IN 2012-2013: INCIDENCE REPORT. Medical and Biological Sciences, 2014, 28, 55.	0.2	3
148	Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2564-2564.	0.6	1
149	Infectious Complications in Children with ALL Treated with ALL-IC-2009 Protocol: Multicenter National Study of Polish Society of Pediatric Hematology and Oncology. Blood, 2014, 124, 5247-5247.	0.6	0
150	Survival and prognostic factors in children with brain tumors: long-term follow-up single center study in Poland. Anticancer Research, 2014, 34, 323-6.	0.5	9
151	Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis. Anticancer Research, 2014, 34, 7379-82.	0.5	10
152	Array Comparative Genomic Hybridization in Pediatric Acute Leukemias. Pediatric Hematology and Oncology, 2013, 30, 677-687.	0.3	2
153	Use of complementary and alternative medicine by children in Europe: Published data and expert perspectives. Complementary Therapies in Medicine, 2013, 21, S34-S47.	1.3	100
154	Dzieci jako dawcy szpiku. Pediatria Polska, 2013, 88, 491-499.	0.1	1
155	Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2013, 57, 794-802.	2.9	196
156	Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study. Leukemia and Lymphoma, 2013, 54, 1256-1262.	0.6	1
157	Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Leukemia and Lymphoma, 2013, 54, 503-506.	0.6	55
158	Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. British Journal of Cancer, 2013, 109, 2523-2532.	2.9	22
159	No Major Complications In Children After Stem Cell Donation At One Year Follow-Up: EBMT Pediatric Diseases Working Party Study. Blood, 2013, 122, 1725-1725.	0.6	1
160	Gene Polymorphism Profile May Predict Late Complications In Patients Undergoing Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 3321-3321.	0.6	0
161	Genetic Mechanisms Of Cytarabine, Etoposide and Daunorubicin Resistance In Pediatric Acute Leukemias. Blood, 2013, 122, 4938-4938.	0.6	O
162	Individual tumor response testing in multiple relapsed acute myeloid leukemia in children. Anticancer Research, 2013, 33, 1189-93.	0.5	0

#	Article	IF	CITATIONS
163	Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma. Bone Marrow Transplantation, 2012, 47, 1530-1534.	1.3	20
164	Przeszczepianie krwi pä™powinowej w polskich oÅrodkach pediatrycznych: raport Polskiej Pediatrycznej Grupy ds. Transplantacji Komórek Krwiotwórczych. Acta Haematologica Polonica, 2012, 43, 265-270.	0.1	1
165	Analiza porównawcza przebiegu neutropenii po chemioterapii i zastosowaniu czynnika wzrostu kolonii granulocytarnych lub jego formy pegylowanej. Pediatria Polska, 2012, 87, 165-168.	0.1	O
166	Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood, 2012, 119, 2935-2942.	0.6	82
167	Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder in Children Treated with Rituximab: The Impact of Viral Load and Non-Lymphoid Tissue Involvement. Biology of Blood and Marrow Transplantation, 2012, 18, S303.	2.0	0
168	Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia. Wspolczesna Onkologia, 2012, 3, 210-214.	0.7	0
169	Strategy of pre-emptive management of Epstein-Barr virus post-transplant lymphoproliferative disorder after stem cell transplantation: results of European transplant centers survey. Wspolczesna Onkologia, 2012, 4, 338-340.	0.7	7
170	Matched Sibling Versus Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Children with Severe Acquired Aplastic Anemia: Experience of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 225-233.	1.0	20
171	Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia. Journal of Applied Genetics, 2012, 53, 83-91.	1.0	8
172	Identification of the genes expression profile associated with the ex vivo resistance to etoposide in childhood acute leukemias. Postepy Higieny I Medycyny Doswiadczalnej, 2012, 66, 401-408.	0.1	4
173	Donor CMV Status Influence On the Outcome of Allogeneic Stem Cell Transplantation (HSCT); A Study by the Infectious Diseases Working Party (IDWP) of the EBMT. Blood, 2012, 120, 465-465.	0.6	0
174	Expression profiles of signal transduction genes in ex vivo drug-resistant pediatric acute lymphoblastic leukemia. Anticancer Research, 2012, 32, 503-6.	0.5	28
175	Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia. Anticancer Research, 2012, 32, 5495-9.	0.5	4
176	Przeszczepianie kom $\tilde{A}^3$ rek krwiotw $\tilde{A}^3$ rczych ze zredukowan $\ddot{A}$ toksyczno $\mathring{A}$ ci $\ddot{A}$ i intensywno $\mathring{A}$ ci $\ddot{A}$ kondycjonowania u dzieci: rola treosulfanu. Pediatria Polska, 2011, 86, 523-531.	0.1	0
177	Rituximab in treatment of post-transplant lymphoproliferative disease after allogeneic stem cell transplantation. Wspolczesna Onkologia, 2011, 3, 155-158.	0.7	1
178	Cerebral complications induced by calcineurin inhibitors in children after haematopoietic stem cell transplantation. Wspolczesna Onkologia, 2011, 3, 159-163.	0.7	1
179	Relapse of Acute Lymphoblastic Leukemia in Children in the Context of Microarray Analyses. Archivum Immunologiae Et Therapiae Experimentalis, 2011, 59, 61-68.	1.0	22
180	A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplantation, 2011, 46, 790-799.	1.3	34

#	Article	IF	CITATIONS
181	Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome. Blood, 2011, 118, 3109-3109.	0.6	O
182	Individualized Tumor Response Testing (ITRT) Profile Has a Prognostic Value in Childhood Acute Lymphoblastic Leukemia (ALL) and Acute Non-Lymphoblastic Leukemia (ANLL): The Multicenter Non-Interventional Long-Term Follow-up Study of Polish Pediatric Leukemia Study Group. Blood, 2011, 118, 1456-1456.	0.6	O
183	Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry. Anticancer Research, 2011, 31, 1453-7.	0.5	6
184	Health-related quality of life among paediatric survivors of primary brain tumours and acute leukaemia. Quality of Life Research, 2010, 19, 191-198.	1.5	34
185	Invasive aspergillosis in children after haematopoietic stem cell transplantation. Wspolczesna Onkologia, 2010, 1, 44-53.	0.7	0
186	Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Research, 2010, 30, 2119-24.	0.5	13
187	Imatinib is a substrate for various multidrug resistance proteins. Neoplasma, 2009, 56, 202-207.	0.7	28
188	Cidofovir for BK Virus–Associated Hemorrhagic Cystitis: A Retrospective Study. Clinical Infectious Diseases, 2009, 49, 233-240.	2.9	112
189	Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia. Annals of Hematology, 2009, 88, 1193-1198.	0.8	1
190	Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplantation, 2009, 43, 121-126.	1.3	42
191	Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplantation, 2009, 43, 757-770.	1.3	323
192	Fatal combined immune hemolytic anemia after double cord blood transplantation in imatinib-resistant CML. Bone Marrow Transplantation, 2009, 44, 383-385.	1.3	9
193	Outcome of treatment of Epstein–Barr virusâ€related postâ€transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transplant Infectious Disease, 2009, 11, 383-392.	0.7	194
194	SU-DD-A3-03: Can Prompt Gamma Emission During Proton Therapy Provide in Situ Range Verification?. Medical Physics, 2009, 36, 2425-2425.	1.6	5
195	Pediatric Sibling Donor Complications of Hematopoietic Stem Cell Collection: EBMT Pediatric Diseases Working Party Study Blood, 2009, 114, 806-806.	0.6	3
196	http://www.termedia.pl/-945-blockade-is-not-effective-in-decreasing-tissue-bulk-in-patients-suffering-from-BPH-an Central European Journal of Urology, 2009, 62, 263-265.	-in-vitro-st	udy,57,1362
197	Gene Expression and Ex Vivo Drug Sensitivity Profiles in Children with Acute Leukemia: An Insight for High-Dose Therapy and Role of Etoposide and Fludarabine Blood, 2009, 114, 2747-2747.	0.6	0
198	Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Research, 2009, 29, 1643-50.	0.5	5

#	Article	IF	CITATIONS
199	Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplantation, 2008, 42, 227-240.	1.3	267
200	Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplantation, 2008, 42, S77-S81.	1.3	39
201	Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?. Medical Hypotheses, 2008, 71, 694-699.	0.8	5
202	322: Role of Rituximab for Prophylactic or Preemptive Therapy of EBV-DNA-emia and Therapy of EBV-PTLD in HSCT Recipients: a Systematic Review. Biology of Blood and Marrow Transplantation, 2008, 14, 118-119.	2.0	0
203	Profil diagnostyczny wznowy ostrej biaÅ,aczki limfoblastycznej. Pediatria Polska, 2008, 83, 128-135.	0.1	O
204	Biochemiczne wykÅ,adniki toksycznoÅ·ci wÄtrobowej w przebiegu chemioterapii u dzieci z chorobami nowotworowymi. Pediatria Polska, 2008, 83, 229-234.	0.1	0
205	The influence of $\hat{l}\pm 1$ -antagonist on the expression pattern of TNF receptor family in primary culture of prostate epithelial cells from BPH patients. Prostate Cancer and Prostatic Diseases, 2008, 11, 88-93.	2.0	8
206	Childhood cancer treatment: an adult comparison. Pediatric Health, 2008, 2, 161-174.	0.3	1
207	Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. Anticancer Research, 2008, 28, 1927-31.	0.5	3
208	Drug Resistance in Childhood Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology, 2007, 8, 59-75.	0.9	22
209	Unusual profiles of pediatric acute lymphoblastic leukemia with MLL gene rearrangement. Leukemia and Lymphoma, 2007, 48, 2083-2086.	0.6	3
210	Komórki hematopoetyczne w szpiku i we krwi obwodowej u chorych na ostrÄ biaÅ,aczkÄ™ limfoblastycznÄ, guzy lite oraz u dzieci zdrowych. Pediatria Polska, 2007, 82, 507-512.	0.1	0
211	Strategies for prevention of infectious complications in children after HSCT in relation to type of transplantation and GVHD occurrence. Reports of Practical Oncology and Radiotherapy, 2007, 12, 149-157.	0.3	O
212	In vitro leukemic cell viability in the presence of alternative remedies might be related to in vivo drug resistance. Pediatric Blood and Cancer, 2007, 49, 106-106.	0.8	1
213	Progenitor cells are responsible for formation primary epithelial cultures in the prostate epithelial model. International Urology and Nephrology, 2007, 39, 851-857.	0.6	9
214	Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology, 2007, 133, 875-893.	1.2	33
215	Infectious Complication in 314 Patients after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation: Risk Factors Analysis and Outcome. Infection, 2007, 35, 421-427.	2.3	75
216	Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting Acta Biochimica Polonica, 2007, 54, 717-726.	0.3	30

#	Article	IF	Citations
217	SU-FF-T-161: Do Obliquity Factors Apply to 30° Scattered Radiation From Megavoltage Photon Beams?. Medical Physics, 2007, 34, 2438-2438.	1.6	O
218	Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia. Anticancer Research, 2007, 27, 1547-51.	0.5	5
219	Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochimica Polonica, 2007, 54, 717-26.	0.3	14
220	Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Research, 2007, 27, 4021-5.	0.5	18
221	Ex vivo activity of thalidomide in childhood acute leukemia. Leukemia and Lymphoma, 2006, 47, 1123-1128.	0.6	3
222	Alternative medicine remedies might stimulate viability of leukemic cells. Pediatric Blood and Cancer, 2006, 46, 94-98.	0.8	22
223	Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2006, 133, 397-399.	1.2	8
224	Thalidomide increases in vitro sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and cytarabine. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 341-345.	1.0	3
225	Keratinocyte Growth Factor for Prophylaxis of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Blood, 2006, 108, 5247-5247.	0.6	0
226	Bone Marrow Stem Cells Infusion in Treatment of Patients with Acute Myocardial Infarction Blood, 2006, 108, 1682-1682.	0.6	0
227	Activity of bortezomib in glioblastoma. Anticancer Research, 2006, 26, 4499-503.	0.5	30
228	Anti-HBs profiles in children treated for neoplastic disease who had been vaccinated against hepatitis B postnatally or as infants. Journal of Hospital Infection, 2005, 60, 73-77.	1.4	8
229	Calcified fibromatosis of the neck in 4-year old girl: Rapid growth, rapid therapy. International Journal of Pediatric Otorhinolaryngology, 2005, 69, 847-852.	0.4	3
230	In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses. Neoplasma, 2005, 52, 74-8.	0.7	3
231	Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia. Anticancer Research, 2005, 25, 2253-8.	0.5	18
232	Is the In Vitro Drug Resistance Profile the Strongest Prognostic Factor in Childhood Acute Lymphoblastic Leukemia?. Journal of Clinical Oncology, 2004, 22, 963-964.	0.8	13
233	Outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplantation, 2004, 34, 129-136.	1.3	39
234	Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis. Pediatric Blood and Cancer, 2004, 42, 195-199.	0.8	10

#	Article	IF	CITATIONS
235	Angiogenic Cytokines: Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Levels in Serum of Children with Hematopoietic Malignancies and Solid Tumors Blood, 2004, 104, 3905-3905.	0.6	0
236	Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) in Children with Acute Lymphoblastic Leukemia Blood, 2004, 104, 4387-4387.	0.6	0
237	Decrease of dual hepatitis B and C virus infections in children with cancer: changes in risk factors over 30 years. Haematologica, 2004, 89, 251-2.	1.7	1
238	Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin. Leukemia, 2002, 16, 820-825.	3.3	11
239	DIFFERENTIAL CHEMOSENSITIVITY IN A CHILD WITH CONGENITAL RELAPSING ACUTE LYMPHOBLASTIC LEUKEMIA. Pediatric Hematology and Oncology, 2002, 19, 355-360.	0.3	3
240	Ex Vivo Drug Resistance Profile in Childhood Acute Myelogenous Leukemia: No Drug is More Effective in Comparison to Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2002, 43, 1843-1848.	0.6	11
241	In Vitro Drug Resistance Profiles of Adult Acute Lymphoblastic Leukemia: Possible Explanation for Difference in Outcome to Similar Therapeutic Regimens. Leukemia and Lymphoma, 2002, 43, 301-307.	0.6	9
242	In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report. Acta Biochimica Polonica, 2002, 49, 221-5.	0.3	0
243	Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: preliminary report. Acta Biochimica Polonica, 2002, 49, 93-8.	0.3	2
244	The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia. Acta Biochimica Polonica, 2002, 49, 99-107.	0.3	2
245	Differences in significance of drug resistance mechanisms between adult and childhood acute lymphoblastic leukemia. Haematologia, 2002, 32, 313-25.	0.2	1
246	A nine-year experience of immunoprophylaxis against hepatitis B virus infection in children with cancer: results from a single institution in Poland. Journal of Hospital Infection, 2001, 48, 298-303.	1.4	4
247	Epidemiologic aspects and preventive strategy of hepatitis B and C viral infections in children with cancer. Pediatric Infectious Disease Journal, 2001, 20, 1042-1049.	1.1	13
248	In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2000, 110, 813-818.	1.2	48
249	Risk of HCV infections among children with cancer and health-care workers in children's hospitals. Infection, 1999, 27, 36-38.	2.3	6